RecruitingHeart Transplant Infection Prevention
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Eligible age
1–17 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Sponsor: Children's Mercy Hospital Kansas City
You may qualify if…
- ✓ Received a heart transplant
- ✓ At least 1 year after transplant
- ✓ At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
- ✓ At least 1 year from anti-thymocyte globulin
- ✓ At least 6 months after pulse dose steroid treatment or basiliximab treatment
- ✓ No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
- ✓ Clinically well
You may not qualify if…
- ✕ History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
- ✕ History of anaphylactic reaction to MMR vaccination
Where it's recruiting
Missouri
Kansas City
Source: ClinicalTrials.gov · NCT07195032 · last updated 2025-09-26